<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To date, there are no curative therapeutic options for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) other than allogeneic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>We treated an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient with 10 microg/kg pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF) for more than 450 d </plain></SENT>
<SENT sid="2" pm="."><plain>The patient's <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">platelet counts increased</z:e> from &lt;10 x 10(9)/l to 50 x 10(9)/l </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> levels increased dramatically and reached over 13 g/dl without additional transfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Adverse events and neutralizing antibodies were not observed during treatment, suggesting that the long-term administration of rHuMGDF might be of clinical benefit to patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>